Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

Overall survival for patients with gastrointestinal stromal tumors (GIST) in the fourth-line setting was 15.1 months versus 6.6 months for placebo, building on impressive progression-free survival results.